Sucampo Pharmaceuticals Inc. (SCMP)
Россия
  • Россия
  • Украина

Sucampo Pharmaceuticals Inc. (SCMP)

Contact Details

4520 East West Hwy Fl 3, Bethesda, Maryland, USA 20814-3392
(301) 961-3400
4520 East West Hwy Fl 3, Bethesda, Maryland, USA 20814-3392

General Information

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

Contact Information

Phone(301) 961-3400
Fax(301) 961-3440
Website 1http://www.sucampo.com
FacebookFacebook
LinkedInLinkedIn
Twitter@Sucampo_Pharma
Thomson Reuters PermID4295900124

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO$5,650,7592014
Divisional Executive VP$1,700,6732014
CAO and Subsidiary Vice President$570,362201440.5%
Divisional Executive VP$1,117,4292014
Former CEO, Former Chief Scientific Officer and Director$183,2822014-78.8%
Former CFO$717,332201452.4%
Chief Scientific Officer$1,812,2142014

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$153 million
Employees159

Ownership

Ticker SymbolSCMP
ExchangeNASDAQ Global Market
Year Founded1996

Stocks

Previous Close10.98
Open10.98
Bid10.74 x 100
Ask10.76 x 200
Day`s Range10.61 - 11.17
52-Week Range9.84 - 28.96
Average Volume (1M)736,149
Forward P/E11.12x
Trailing P/E12.14x
Beta1.42x
Market Cap.$525.06 Million
Last Dividend Amount0
1y Target Price Est.29.67

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue55,36833,44834,88429,480
Cost of Revenue18,0755,2867,2606,110
Gross Profit37,29328,16227,62423,370
Research Development11,3468,3687,1246,793
Selling General and Administrative14,3798,1378,9206,923
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses43,80021,79123,30419,826
Other Income/Expenses Net----
Earnings Before Interest and Taxes11,56811,65711,5809,654
Interest Expense6,070243265276
Income Before Tax9,46611,56313,4319,215
Income Tax Expense(685)4,3273,8552,807
Minority Interest----
Net Income from Continuing Ops10,1517,2369,5766,408
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income10,1517,2369,5766,408
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares10,1517,2369,5766,408